Table 1.

Data from selected studies relating the fractures and the use of PPIs.

References	Year	Country	Kind of Study	Participants		Age (Years)	Fracture Sites	Fractures		PPI Use	PPI Use Duration
				PPI Users (n)	PPI Non-Users (n)			PPI Users (n)	PPI Non-Users (n)
Roux et al. [16]	2009	Germany and France	Prospective cohort	61	1150	65.9 ± 6.5	Vertebral fractures	14	128	Omeprazole	12 months
				61	1150		Low-trauma fractures	26	233
Gray et al. [17]	2010	United States	Prospective cohort	3396	148,394	64	Hip, spine, forearm, or wrist and total fractures	584	18,191	Lanzoprazole and omeprazole	12–36 months
Khalili et al. [12]	2012	United States	Prospective cohort	5431	74,558	66.8	Hip	149	744	*	24 months
Lewis et al. [18]	2014	Australia	Prospective cohort	120	925	78.5 ± 3.4	Hip—major fractures	17	89	Omeprazole, esomeprazole, pantoprazole, lansoprazole or rabeprazole	12 months
				120	925		Hip—fractures	21	77
Moberg et al. [19]	2014	Sweden	Prospective cohort	6416 **		56.4	*	1137 **		*	*
Total				9189	227,102			811	19,462

* Not reported by the author in his study; ** Described only the total number of participants and fractures.